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Opioid use disorders and hospital palliative care
among patients with gastrointestinal cancers
Ten-year trend and associated factors in the U.S. from 2005 to
2014
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Abstract
This study aimed to analyze the trends of opioid use disorders, cannabis use disorders, and palliative care among hospitalized
patients with gastrointestinal cancer and to identify their associated factors.
We analyzed the National Inpatient Sample data from 2005 to 2014 and included hospitalized patients with gastrointestinal
cancers. The trends of hospital palliative care and opioid or cannabis use disorders were analyzed using the compound annual
growth rates (CAGR) with Rao-Scott correction for x2 tests. Multivariate logistic regression analyses were performed to identify the
associated factors.
From 2005 to 2014, among 4,364,416 hospitalizations of patients with gastrointestinal cancer, the average annual rates of opioid
and cannabis use disorders were 0.4% (n=19,520), and 0.3% (n=13,009), respectively. The utilization rate of hospital palliative care
was 6.2% (n=268,742). They all sharply increased for 10 years (CAGR=9.61%, 22.2%, and 21.51%, respectively). The patients with
a cannabis use disorder were over 4 times more likely to have an opioid use disorder (Odds ratios, OR=4.029; P< .001). Hospital
palliative care was associated with higher opioid use disorder rates, higher in-hospital mortality, shorter length of hospital stay, and
lower hospital charges. (OR=1.527, 9.980, B=0.054 and 0.386; each of P< .001)
The temporal trends of opioid use disorders and hospital palliative care use among patients with gastrointestinal cancer increased
from 2005 to 2014, which is mostly attributed to patients with a higher risk of in-hospital mortality. Cannabis use disorders were
associated with opioid use disorders. Palliative care was associated with both reduced lengths of stay and hospital charge.
Abbreviations: AHRQ = the Agency for Healthcare Research and Quality, APR-DRG = all-patient refined diagnosis-related
group, C.I.s = confidence intervals, CAGR = Compound Annual Growth Rate, CMS = Centers for Medicare and Medicaid Services,
EOL = end-of-life, HCUP = the Healthcare Cost and Utilization Project, ICD-9-CM = International Classification of Diseases, Ninth
Revision, Clinical Modification, LOS = length of hospital stay, NIS = National Inpatient Sample, OR = odds ratios, PDMPs = the
Prescription Drug Monitoring Programs.
Keywords: cannabis use disorders, gastrointestinal neoplasms, hospital charges, in-hospital mortality, opioid use disorders,
palliative care
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Every year over 1.7 million people are diagnosed with cancer in
the United States.[1] Most of the patients suffered from cancer
pain and controllable symptoms during their end-of-life time. For
that reason, the integration of palliative care into standard
oncology care regardless of the severity of the cancer is insisted
upon in current oncology treatment.[2]
Opioid medication can mitigate the cancer-related symptoms
and provide comfort to patients along with the cancer treatment.
Palliative care guideline suggests the use of opioid drugs for
cancer patients.[3]
There have been growing concerns about the possibility of
opioid misuse and overuse, particularly in patients who suffered
from chronic pain, such as cancer pain or chronic low back
pain.[4,5] For gastrointestinal cancer patients, weak opioids such
as codeine, to strong opioid medications, such as morphine,
oxycodone, hydromorphone, or fentanyl, could be prescribed to
control pain and relieve anxiety.[6]
In 2016, more than 11.5 million people reported misuse of
prescription pain medicine,[7] and 115 Americans die every day
from an opioid overdose.[8] On October 27, 2017, the
government administration declared the opioid crisis a national
public health emergency under section 319 of the Public Health
Service Act. This declaration was renewed on October 18,
2018, because of the continued consequences of the opioid
epidemic.
Cannabis is classified as a Schedule I controlled substance
because of its high potential for dependence and uncertain
medical benefits. Over the past 2 decades, citizen-initiated public
votes have driven medical and recreational cannabis use. Thirty
three states and the District of Columbia have adopted marijuana
legalization in some form (National Conference of State
Legislatures, 2018). Cannabis remains the most commonly used
illicit drug in the United States, with an estimated 22.2 million
people using it currently, and an additional 2.4 million people
reporting first-time use annually.[9] As a consequence, there
were increasing emergency department visits related to cannabis
use from 2006 to 2014.[10] Although there is an ongoing debate
about whether cannabis is a gateway drug[11] or a substitute for
opioid use,[12] little attention has been given to the impacts of
marijuana legalization on opioid-related hospitalization among
patients with gastrointestinal cancer.
This study aimed to investigate the trends of opioid use
disorders, cannabis use disorders, and hospital palliative care
among hospitalized patients with gastrointestinal cancer and to
identify their associated factors.
2. Methods
2.1. Data source
This study was based on the Nationwide Inpatient Sample (NIS).
NIS is the largest publicly available, all-payer U.S. hospital
inpatient dataset. It contains a 20% stratified sample of hospital
inpatient stays from across the U.S. The dataset captures
discharge information from hospital inpatient stays and belongs
to the family of the Healthcare Cost and Utilization Project
(HCUP) sponsored by the Agency for Healthcare Research and
Quality (AHRQ).[13] The NIS can be weighted to generate
national estimates. We used a 10-year data from 2005 to 2014.
The use of theNIS dataset is entirely anonymous, with no risk of a
confidentiality breach. An Institutional Review Board approval
was not required. We completed a data user agreement with the
AHRQ before using the NIS database.
2.2. Patient cohort selection
The 2005 to 2014 NIS datasets were used for analysis. We
applied survey weights and adjustments to provide annual
national population estimates. Our population of interest was
hospitalized patients with gastrointestinal cancer. Patients were
identified as having cancer in the digestive tract, including oral,
esophagus, stomach, liver, gall bladder, pancreas, small intestine,
and large intestine as the principal diagnosis, opioid use (abuse,
dependence, unspecified use, poisoning), and palliative care by
using the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes (Supplementary Ta-
ble 1, http://links.lww.com/MD/E379). Quality control proce-
dures performed by the HCUP have demonstrated reliability and
accuracy, mainly when data contains the principal diagnosis.[14]
Patient-level characteristics from the database included age,
gender, race, number of comorbidities (as a continuous variable),
the severity of illness using all-patient refined diagnosis-related
group (APR-DRG), the primary payer (Medicare, private
insurance, Medicaid, others), and the zip code-based annual
median household income.
2.3. Variables of interest
The primary outcomes were the proportion of opioid use
disorders, cannabis use disorder, palliative care, and in-hospital
death. We calculated the total cost of each hospitalization
provided by HCUP by applying hospital-specific and group-
average all-payer inpatient cost-to-charge ratios from the Centers
for Medicare and Medicaid Services (CMS) to the reported
hospital charges. Hospital charges were then adjusted for the
annual inflation rate using CMS estimates and were expressed as
annual means with 95% confidence intervals (C.I.s) in 2014 U.S.
dollars.[15]
2.4. Statistical analysis
First, the compound annual growth rate (CAGR) was used to
quantify temporal trends of the annual number of opioid use
disorders and cannabis use disorders, and hospital palliative
care in patients with gastrointestinal cancer. Its statistical
significance was tested by Rao-Scott correction for x2 tests for
categorical variables. The CAGR supposes that year A is x and
year B is y, and CAGR= (y/x) [1/(B-A)]-1 has been widely used for
health care valuation.[16,17] Multivariate logistic regression
analyses were performed to determine the relationship of patient
demographics and socioeconomic status with cannabis use
disorders, opioid use disorders, hospital palliative care, in-
hospital mortality, length of hospital stay (LOS), and hospital
charges.
To evaluate the impact of missing data on opioid use disorders,
we compared the baseline characteristics between the missing and
analyzed samples characteristics. We calculated imputed absent
hospital charges using regression analysis models. There were no
statistical differences between the baseline characteristics of the
interpreted and missing data. The model was determined to be
stable, and the assumption of randomly missing data was found
to be reasonable using the observed data. All analyses were
performed using SAS statistical software version 9.4 (SAS
Hwang et al. Medicine (2020) 99:25 Medicine
2
Institute Inc., Cary, NC). All reported P values were 2-tailed, and
P value <.05 was considered statistically significant.
3. Results
3.1. Descriptive data and temporary trends of
hospitalization of patients with gastrointestinal cancer
From 2005 to 2014, the NIS database contained 77,394,755
hospital inpatient stays and 4,364,416 hospitalizations of
patients with gastrointestinal cancer. Table 1 presents the
descriptive characteristics of patients and hospitalizations.
Opioid use disorders and cannabis use disorder were less than
1.0% of the total hospitalizations (0.4%, n=19,520; 0.3%, n=
13,009); 6.2% of the patients received palliative care during the
hospitalization (n=268,742). Overall in-hospital mortality rate
was 6.7% (n=294,567). The average LOS and inflation-adjusted
hospital charges were 7.3 days and $43,077 per hospitalization,
respectively.
Table 1
Characteristics of the population (N=4,364,416).
Total 2005 2008 2011 2014
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
N 880,510 71,721 88,916 103,027 98,214
Weighted N (the national estimate) 4,364,416 352,920 434,458 494,623 491,070
Opioid use disorders
No 4,344,895 99.6% 351,898 99.7% 433,087 99.7% 492,437 99.6% 487,820 99.3%
Yes 19,520 0.4% 1,023 0.3% 1,371 0.3% 2,186 0.4% 3,250 0.7%
Cannabis use disorders
No 4,351,407 99.7% 352,624 99.9% 433,555 99.8% 493,016 99.7% 488,560 99.5%
Yes 13,009 0.3% 297 0.1% 903 0.2% 1,607 0.3% 2,510 0.5%
Palliative care
No 4,095,673 93.8% 346,448 98.2% 419,342 96.5% 456,032 92.2% 439,060 89.4%
Yes 268,742 6.2% 6,472 1.8% 15,116 3.5% 38,591 7.8% 52,010 10.6%
Age group
< 30 49,020 1.1% 4,089 1.2% 5,228 1.2% 4,737 1.0% 5,455 1.1%
30-39 90,483 2.1% 7,411 2.1% 9,290 2.1% 9,881 2.0% 10,300 2.1%
40-49 330,613 7.6% 26,995 7.6% 33,132 7.6% 35,838 7.2% 34,275 7.0%
50-59 868,505 19.9% 62,931 17.8% 84,805 19.5% 100,788 20.4% 100,730 20.5%
60-69 1,125,516 25.8% 81,089 23.0% 108,460 25.0% 129,980 26.3% 138,215 28.1%
70-79 1,073,725 24.6% 95,150 27.0% 107,460 24.7% 120,044 24.3% 117,910 24.0%
≥ 80 826,553 18.9% 75,255 21.3% 86,082 19.8% 93,355 18.9% 84,185 17.1%
Male sex 2,406,438 55.1% 190,210 53.9% 238,631 54.9% 272,580 55.1% 274,225 55.8%
Race
Black 565,092 12.9% 36,783 10.4% 52,095 12.0% 69,575 14.1% 65,200 13.3%
Hispanic 404,013 9.3% 30,187 8.6% 37,231 8.6% 46,359 9.4% 47,125 9.6%
Asian or Pacific Islander 168,059 3.9% 12,393 3.5% 19,315 4.4% 16,294 3.3% 19,195 3.9%
Native American/Other 140,988 3.2% 9,247 2.6% 14,895 3.4% 14,797 3.0% 15,795 3.2%
White 3,086,265 70.7% 264,310 74.9% 310,922 71.6% 347,598 70.3% 343,755 70.0%
Median household income
0 to 25th percentile 1,178,279 27.0% 86,867 24.6% 112,267 25.8% 137,753 27.9% 136,785 27.9%
26th to 50th percentile 1,070,919 24.5% 82,920 23.5% 114,337 26.3% 116,046 23.5% 131,825 26.8%
51st to 75th percentile 1,050,925 24.1% 90,927 25.8% 99,044 22.8% 126,107 25.5% 113,320 23.1%
76th to 100th percentile 1,064,292 24.4% 92,206 26.1% 108,810 25.0% 114,718 23.2% 109,140 22.2%
Primary payer
Medicare 2,410,267 55.2% 204,491 57.9% 236,663 54.5% 275,101 55.6% 270,700 55.1%
Medicaid 421,883 9.7% 28,185 8.0% 38,703 8.9% 48,956 9.9% 55,730 11.3%
Uninsured 144,907 3.3% 10,826 3.1% 11,025 2.5% 15,234 3.1% 13,690 2.8%
Other 110,106 2.5% 6,698 1.9% 12,553 2.9% 13,132 2.7% 12,105 2.5%
Private insurance 1,277,253 29.3% 102,720 29.1% 135,515 31.2% 142,200 28.7% 138,845 28.3%
Number of Comorbidities
∗
2.73 1.90 2.46 1.58 2.86 1.80 3.22 1.93 2.08 2.00
In-hospital mortality
No 4,069,849 93.3% 322,986 91.5% 403,119 92.8% 463,149 93.6% 461,445 94.0%
Yes 294,567 6.7% 29,934 8.5% 31,339 7.2% 31,475 6.4% 29,625 6.0%
Severity of illness subclass
APR-DRG 0,1, lowest 704,293 16.1% 49,611 14.1% 44,228 10.2% 44,106 8.9% 173,350 35.3%
APR-DRG 2 1,655,292 37.9% 147,215 41.7% 166,668 38.4% 163,846 33.1% 185,250 37.7%
APR-DRG 3 1,511,045 34.6% 120,928 34.3% 167,713 38.6% 206,665 41.8% 104,960 21.4%
APR-DRG 4, highest 493,785 11.3% 35,166 10.0% 55,849 12.9% 80,006 16.2% 27,510 5.6%
LOS
∗
7.30 7.82 8.10 9.09 7.67 8.15 7.07 7.66 6.74 6.95
Inflation adjusted hospital charges
∗
43,077 61,040 43,426 61,508 44,890 62,492 44,198 65,594 42,108 58,072
∗
Mean/SD.
APR-DRG = all-patient refined diagnosis-related group, LOS = length of stay.
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Figure 1 presents the trends and the CAGRs of opioid use
disorders, cannabis use disorders, and the annual numbers of
hospitalization. The annual rate of opioid use disorders,
cannabis use disorder, and hospitalization have increased over
the past decade (CAGR=9.61%, 22.20%, and 3.74%; each
P< .0001).
Hospital palliative care has increased by over 5 times from
2005 (1.8%) to 2014 (10.6%) (Table 1). There was a sharp
increase in the period from 2008 to 2009 (Fig. 1). In-hospital
mortality, LOS, and inflation-adjusted hospital charges have
decreased over time (CAGR=3.72%, 2.02% and 0.34%);
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Figure 1. The temporal trends of the total number of hospitalizations with gastrointestinal cancers and opioid, and cannabis-use disorders among them from 2005
to 2014. ∗CAGRs: The compound annual growth rates.




























































Figure 2. The temporal trends of total hospital charges, inflation-adjusted hospital charges during each hospitalization, and the annual rate of hospital palliative care
and mortality among patients with gastrointestinal cancers from 2005 to 2014.
∗
CAGRs: The compound annual growth rates.
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3.2. Factors associated with opioid use disorders,
palliative care, length of hospital stay, and hospital
charges (log-transformed multivariate regression analysis)
Table 2 shows the factors associated with opioid use disorders.
The patients with a cannabis use disorder weremore likely related
to opioid use disorders by over 4 times than patients without it
(Odds ratio, OR=4.029, 95% Confidence Interval, CI=3.367–
4.823). Patients who received palliative care during the
hospitalization were more associated with opioid use disorders
(OR=1.423, 95%CI=1.263–1.604). Younger groups, Black
and Hispanic races, and public health insurance beneficiaries
were more vulnerable to opioid use disorders (see Table 2).
Table 3 presents the odds ratios of hospital palliative care.
Patients of older ages were more likely to receive palliative care
consultation or services. Hospital palliative care was associated
with an increase in in-hospital mortality (OR=9.980, 95%CI=
9.734–10.233). Opioid and cannabis use disorders were not
related to the rise of in-hospital mortality (Supplementary Table 2,
http://links.lww.com/MD/E380). Private insurance beneficiaries
and uninsured patients showed a higher tendency of in-hospital
mortality than the public insurance beneficiaries and others.
Tables 4 and 5 shows the factors associated with the LOS and
hospital charges (inflation-adjusted). Palliative care was associ-
ated with reductions in the length of hospital stay and hospital
charges. Opioid or cannabis use disorders were not associated
with an increase in the LOS and hospital charges.
4. Discussion
4.1. The trends and associated factors of opioid use
disorders in patients with gastrointestinal cancer
The trend indicated an increase in opioid use disorders among
hospitalizations of patients with gastrointestinal cancer (see
Table 1 and Fig. 1). It is consistent with the nationwide trend of
an opioid epidemic.[18] The overuse and misuse of prescribed
opioids were the leading causes of this issue, and both patients
and their caregivers and family were affected. We could observe
an incremental trend of cannabis use disorders, as well (Table 1).
A recent study suggested that medical cannabis law appears to
have contributed to an increasing prevalence of illicit cannabis
use and cannabis use disorders.[19]
In the regression analysis to investigate the association of
cannabis use disorders and opioid use disorders, patients who
were diagnosed with a cannabis use disorder were over 4 times
more likely to have an opioid use disorder (Table 2). From the
early 90s, in the west coast states, such as California, Oregon, and
Washington, medical cannabis legalization has been enacted to
reduce opioid overuse death. The law has appeared to be
valid.[20] However, increasing cannabis use disorder rates cause
a growing concern about opioid and other substance use
disorders.[9] Cannabis use disorder rates increase along with
the increasing trend of opioid use disorders in our analysis. On
October 19, 2009, the government issued a memo stating that it
would not prosecute marijuana users and sellers who complied
with the state laws for cannabis use.[21] We speculated that the
year 2010 would be the beginning of an opioid epidemic phase
because of the drug policies influencing public attitudes and
behaviors on opioids, cannabis, and other substances. Although
there is an ongoing debate whether marijuana is a gateway drug,
our findings imply that cannabis and opioid use can mutually
increase each other, based on the reports from the survey[22] and
claim data.[10] Continuous use of cannabis for either medicinal or
recreational purposes may lead to increased dependence and
higher tolerance levels. Therefore, the medical and recreational
use of marijuana can potentially lead to more severe health
outcomes, such as cannabis abuse or addiction. Although the
prevalence of cannabis use disorders is still lower in hospitalized
patients, the medical and illicit use of cannabis to younger
patients need to be monitored to prevent further substance
addiction as with the Prescription DrugMonitoring Programs for
opioid overdose. Because younger age is at higher risk of cannabis
use disorders than opioid use disorders.
4.2. The underutilization, disparities, and late referral to
hospital palliative care in patients with gastrointestinal
cancer
Our study demonstrates that the hospital palliative care for
gastrointestinal cancer has increased considerably over the past
Table 2
Factors associated with opioid use disorders.
Odds ratios 95% CIs P value
Cannabis use disorders
No Reference
Yes 4.029 3.367 4.823 <.001
Hospital palliative care
No Reference
Yes 1.423 1.263 1.604 <.001
In-hospital mortality
No Reference
Yes 0.855 0.739 0.990 .0358
Year 1.069 1.055 1.083 <.001
Age group
< 30 Reference
30-39 2.005 1.406 2.858 <.001
40-49 2.236 1.615 3.097 <.001
50-59 2.047 1.485 2.822 <.001
60-69 0.950 0.684 1.321 .001
70-79 0.263 0.185 0.372 <.001
≥ 80 0.113 0.077 0.166 <.001
Male sex 1.556 1.453 1.666 <.001
Race
White Reference
Black 1.264 1.164 1.371 <.001
Hispanic 1.156 1.050 1.274 <.001
Asian or Pacific Islander 0.338 0.254 0.451 <.001
Native American/Other 0.942 0.787 1.127 .231
Median household income
76th to 100th percentile Reference
51st to 75th percentile 0.985 0.890 1.091 .918
26th to 50th percentile 0.865 0.781 0.958 <.001
0–25th percentile 1.093 0.995 1.201 <.001
Primary payer
Private insurance Reference
Medicare 2.336 2.104 2.593 .002
Medicaid 4.071 3.705 4.472 <.001
Uninsured 2.140 1.840 2.490 .562
Other 1.866 1.542 2.258 .161
Number of comorbidities 1.314 1.291 1.337 <.001
Severity of illness subclass
APR-DRG 0,1, lowest Reference
APR-DRG 2 0.826 0.744 0.917 .154
APR-DRG 3 0.842 0.755 0.939 .026
APR-DRG 4, highest 0.570 0.493 0.660 <.001
APR-DRG = all-patient refined diagnosis-related group, CI = confidence interval.
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10 years (Fig. 2). This remarkable increase was mostly due to the
accumulating evidence of palliative care benefits, an increase in
the number of hospital palliative care programs, and implemen-
tation of the Affordable Care Act.[23,24]
However, only 6.16% of the patients could be served by
palliative care for 10 years. Palliative cares were underutilized for
hospitalized patients even in cases of advanced cancer.[24] In the
real world, palliative care was commonly utilized by patients who
were dying.[23] As an extension of the hospital palliative care,
some reports show us the probability of in-home palliative
care.[25] Systematic implementation of ambulatory and hospital
palliative services need to be extended among the broader
population.[26]
We could notice the delayed referral to palliative care (Table 3).
The patients who were severely sick and of older age (Medicare)
were referred for hospital palliative care, resulting in palliative
care being associated with higher odds of in-hospital mortality
(Table 3). In the study of the pattern of palliative care delivery
using the SEER-Medicare linked database, 40% of the patients
received palliative care consults in the last 7 days of life.[27,28]
Promotion of earlier provision of palliative care consultation is
needed at the time of enrollment to the cancer registry.[29,30]
4.3. Safety of palliative care related to opioid use
disorders
In our study, we observed that in-hospital mortality and the
length of hospital stay decreased over the past 10 years, contrary
to the increase in the total number of hospitalizations (see Fig. 1).
It could be interpreted in that more patients with gastrointestinal
cancers choose their home or community rather than hospitals as
the place for their end-of-life (EOL) time. A recent study reported
that the terminally ill patients tend to spend their EOL time to
stay with their family or caregivers out of the hospital, rather
than in the intensive care unit.[31] Palliative care highlights the
advanced care plan. If widely utilized, palliative care, and
advanced care planning can help to encourage the patient
decision where they stay and whom they stay with at their
EOL.[32] A broader distribution of home or community base
palliative and hospice care is needed to meet this trend for this
population as well.[33]
In our study, opioid and cannabis use disorders did not
increase the in-hospital mortality rates (Supplementary Table 2,
http://links.lww.com/MD/E380). However, the opioid use disor-
der rates were associated with the hospital palliative care
(Table 3). The American society of clinical oncology recom-
mended the Prescription Drug Monitoring Programs (PDMPs)
for pain medication of patients with cancer, and opioid-induced
death of these patients are 10 times less likely than those of the
general population.[34–36] In our study, it is difficult to recognize
whether it comes from prescribed medicinal or non-medical
purpose consumption because the NIS data set shows all
diagnoses at discharge. No matter what the association between
opioid use disorder and palliative care is, our result implies that
physicians or palliative care specialists should pay attention to
check the history of prescription of opioids and diagnoses of
opioid use disorders.
4.4. Effectiveness of hospital palliative care related to in-
hospital mortality, length of hospital stay, and hospital
charges
Hospital charges for patients with gastrointestinal cancers
slightly decreased from 2005 to 2014 (CAGR=0.34%,
P< .0001) (Fig. 2). Most previous studies have reported that
early introduction of palliative care shows favorable effects on
health care utilization and costs, such as decreased LOS, in-
hospital death, and hospital cost.[37,38] In a recent meta-analysis
from 6 observational studies about the economics of hospital
palliative care, May et al[38] reported that early hospital palliative
care within 3 days of admission reduced the hospital cost for
patients with cancer by $4,251 compared to general care. The
cost-saving from reduced LOS and reduced intensity of treatment
has been estimated to accrue due to early palliative care.
4.5. Limitations and strengths
Since this study was a retrospective review of hospital discharge-
based data, there are several significant limitations. First, this
Table 3
Factors associated with hospital palliative care.
Odds ratios 95% CIs P value
Opioid use disorders
No Reference
Yes 1.527 1.355 1.722 <.001
Cannabis use disorders
No Reference
Yes 1.032 0.873 1.219 .712
In-hospital mortality
No Reference
Yes 9.744 9.509 9.985 <.001
Year 1.286 1.281 1.291 <.001
Age group
< 30 Reference
30–39 1.662 1.456 1.896 <.001
40–49 1.723 1.530 1.940 <.001
50–59 1.804 1.608 2.025 .0018
60–69 2.038 1.816 2.287 <.001
70–79 2.415 2.147 2.716 <.001
≥ 80 3.341 2.970 3.759 <.001
Male sex 0.926 0.909 0.944 <.001
Race
White Reference
Black 1.201 1.167 1.235 <.001
Hispanic 1.119 1.083 1.157 .513
Asian or Pacific Islander 1.198 1.145 1.254 <.001
Native American/Other 1.040 0.988 1.096 .003
Median household income
76th to 100th percentile Reference
51st to 75th percentile 0.934 0.910 0.959 <.001
26th to 50th percentile 0.863 0.840 0.886 <.001
0 to 25th percentile 0.826 0.804 0.848 <.001
Primary payer
Private insurance Reference
Medicare 0.725 0.705 0.746 <.001
Medicaid 1.179 1.139 1.219 .209
Uninsured 1.165 1.106 1.227 .787
Other 2.094 2.001 2.193 <.001
Number of comorbidities 0.950 0.944 0.955 <.001
Severity of illness subclass
APR-DRG 0,1, lowest Reference
APR-DRG 2 1.145 1.112 1.180 <.001
APR-DRG 3 1.887 1.829 1.947 <.001
APR-DRG 4, highest 1.910 1.836 1.988 <.001
APR-DRG = all-patient refined diagnosis-related group, CI = confidence interval.
Hwang et al. Medicine (2020) 99:25 Medicine
6
study only included discharge data, and no actual medical
assessments were included. In addition, the hospital discharge-
based database does not provide information on actual
consumption, dosage, or use patterns of opioids, cannabis, or
other substances. Second, we relied on the ICD-9-CM codes that
may have limited accuracy in capturing the actual number of
persons who used opioids, cannabis, and other substances with
or without mental health conditions because of incorrect coding
or missing data from coding practices and awareness of clinicians
differences.[10] Furthermore, the identification of persons who
used illicit drugs with mental health conditions was significantly
underestimated, considering the low sensitivity and high
specificity in the weighted estimates from the discharge data-
set.[39] This study cannot address the potential for unrecognized
coding errors or unreported events that could influence the
results. Third, our analysis could not fully specify the stages and
onsets of gastrointestinal cancers. Besides, the temporal relation-
ship, that is, the opioid use disorders occurred before admission
that was the cause of hospitalization, or occurred during the
hospitalization, as an unintended overdose from the hospital-
prescribed medication was not investigated. We were also not
able to examine whether cannabis use was initiated before the
opioid use. Future studies need to consider this information using
other datasets. Given the significant and recent data from a
nationally representative dataset, we believe that the temporal
trends and associated factors of opioid use disorders among
hospitalized patients with gastrointestinal cancers are likely
generalizable to most patients with gastrointestinal cancers.
Table 4
Factors associated with the length of hospital stay.
Coefficient, b SE P value Coefficient, b [Log Transform] SE P value
Opioid use disorders
No Reference
Yes 0.334 0.127 .009 0.053 0.011 <.001
Cannabis use disorders
No Reference
Yes 0.658 0.119 <.001 0.055 0.013 <.001
Hospital palliative care
No Reference
Yes 0.586 0.040 <.001 0.054 0.004 <.001
In-hospital mortality
No Reference
Yes 0.295 0.055 <.001 0.198 0.004 <.001
Year 0.089 0.003 <.001 0.009 0.000 <.001
Age group
< 30 Reference
30–39 0.0001 0.114 > .99 0.0538 0.009 <.001
40–49 0.324 0.100 .001 0.032 0.008 <.001
50–59 0.495 0.098 <.001 0.015 0.007 .044
60–69 0.254 0.098 .010 0.043 0.007 <.001
70–79 0.058 0.100 .563 0.075 0.008 <.001
≥ 80 0.053 0.101 .601 0.104 0.008 <.001
Male sex 0.260 0.016 <.001 0.044 0.001 <.001
Race
White Reference
Black 0.515 0.027 <.001 0.044 0.002 <.001
Hispanic 0.140 0.030 <.001 0.003 0.003 .266
Asian or Pacific Islander 0.019 0.046 .675 0.021 0.004 <.001
Native American/Other 0.373 0.051 <.001 0.021 0.004 <.001
Median household income
76th to 100th percentile Reference
51st to 75th percentile 0.028 0.023 .216 0.005 0.002 .026
26th to 50th percentile 0.005 0.023 .823 0.012 0.002 <.001
0 to 25th percentile 0.108 0.023 <.001 0.023 0.002 <.001
Primary payer
Private insurance Reference
Medicare 0.197 0.024 <.001 0.013 0.002 <.001
Medicaid 0.601 0.036 <.001 0.020 0.003 <.001
Uninsured 0.382 0.047 <.001 0.027 0.004 <.001
Other 0.231 0.050 <.001 0.054 0.005 <.001
Number of comorbidities 0.028 0.006 <.001 0.002 0.000 <.001
Severity of illness subclass
APR-DRG 0,1, lowest Reference
APR-DRG 2 0.048 0.019 .012 0.017 0.002 <.001
APR-DRG 3 2.382 0.024 <.001 0.281 0.002 <.001
APR-DRG 4, highest 8.317 0.052 <.001 0.719 0.004 <.001
APR-DRG = all-patient refined diagnosis-related group, SE = standard error.
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5. Conclusion
This study shows that opioid use disorders and hospital palliative
care among hospitalizations of patients with gastrointestinal
cancers steadily increased from 2005 to 2014 in U.S. hospitals.
Opioid use disorders were associated with cannabis use disorders
and palliative care. Prescription of opioids or dispensing cannabis
for patients with cancers should be performed with caution.
Delayed provision of palliative care could be associated with
higher in-hospital mortality. Even though the overall rate of
provision of palliative care was still low, the hospital palliative
care for patients with gastrointestinal cancers showed a cost-
saving effect.
Acknowledgments
We acknowledge all of the HCUP Data Partners that contribute
to HCUP. A current list of the HCUP Data Partners is linked the
following the HCUP-US web page (www.hcup-us.ahrq.gov/
hcupdatapartners.jsp).
Author contributions
Conceptualization: Pearl C. Kim, Ji Won Yoo.
Data curation: Jay J. Shen.
Formal analysis: Jay J. Shen, Sun Jung Kim, Sung-Youn Chun.
Investigation: Jay J. Shen, Sun Jung Kim, Pearl C. Kim, Ji Won
Yoo.
Table 5
Factors associated with hospital charges (Inflation-adjusted).
Coefficient, b SE P value Coefficient, b [Log Transform] SE P value
Opioid use disorders
No Reference
Yes 3,276.820 969.238 .001 0.102 0.016 <.001
Cannabis use disorders
No Reference
Yes 4,881.700 841.539 <.001 0.066 0.019 <.001
Hospital palliative care
No Reference
Yes 12,528.210 311.989 <.001 0.386 0.005 <.001
In-hospital mortality
No Reference
Yes 4,103.200 445.400 <.001 0.213 0.006 <.001
Year 420.760 22.231 <.001 0.012 0.000 <.001
Age group
< 30 Reference
30–39 2,604.110 962.593 .007 0.074 0.013 <.001
40–49 4,450.400 874.114 <.001 0.037 0.011 .001
50–59 5,215.880 857.129 <.001 0.024 0.011 .024
60–69 4,561.610 860.873 <.001 0.033 0.011 .003
70–79 5,618.790 870.660 <.001 0.013 0.011 .237
≥ 80 8,432.670 872.860 <.001 0.037 0.011 .001
Male sex 830.870 124.565 <.001 0.011 0.002 <.001
Race
White Reference
Black 1,712.480 197.302 <.001 0.050 0.003 <.001
Hispanic 10,068.860 256.702 <.001 0.248 0.004 <.001
Asian or Pacific Islander 11,562.840 422.132 <.001 0.253 0.006 <.001
Native American/Other 5,146.230 391.645 <.001 0.107 0.006 <.001
Median household income
76th to 100th percentile Reference
51st to 75th percentile 2,801.960 189.479 <.001 0.070 0.003 <.001
26th to 50th percentile 5,856.770 181.567 <.001 0.146 0.003 <.001
0–25th percentile 6,928.720 183.112 <.001 0.178 0.003 <.001
Primary payer
Private insurance Reference
Medicare 398.590 192.188 .038 0.024 0.003 <.001
Medicaid 196.860 265.326 .458 0.044 0.004 <.001
Uninsured 4,804.390 310.463 <.001 0.094 0.006 <.001
Other 5,736.210 381.354 <.001 0.251 0.008 <.001
Number of comorbidities 152.620 45.948 0.001 0.001 0.001 .098
Severity of illness subclass
APR-DRG 0,1, lowest Reference
APR-DRG 2 1,362.950 150.292 <.001 0.039 0.003 <.001
APR-DRG 3 10,588.300 187.023 <.001 0.258 0.003 <.001
APR-DRG 4, highest 59,613.730 438.985 <.001 0.955 0.005 <.001
APR-DRG = all-patient refined diagnosis-related group, SE = standard error.
Hwang et al. Medicine (2020) 99:25 Medicine
8
Methodology: Jay J. Shen, Sung-Youn Chun.
Project administration: Pearl C. Kim, David Byun.
Resources: Ji Won Yoo.
Software: Sun Jung Kim.
Supervision: Jay J. Shen, Se Won Lee.
Validation: Sung-Youn Chun, Ji Won Yoo.
Visualization: Jinwook Hwang.
Writing – original draft: Jinwook Hwang.
Writing – review& editing: JinwookHwang, Jay J. Shen, SeWon
Lee.
References
[1] Cancer Statistics. April 2018. Available at: https://www.cancer.gov/
about-cancer/understanding/statistics. Accessed April 24, 2019 from
https://www.cancer.gov/about-cancer/understanding/statistics
[2] Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into
standard oncology care: American Society of Clinical Oncology Clinical
Practice Guideline update. J Clin Oncol 2017;35:96–112.
[3] Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the
treatment of cancer pain: evidence-based recommendations from the
EAPC. Lancet Oncol 2012;13:e58–68.
[4] Sherry TB, Sabety A, Maestas N. Documented pain diagnoses in adults
prescribed opioids: results from the National Ambulatory Medical Care
Survey, 2006–2015. Ann Intern Med 2018;169:892–4.
[5] Sun EC, Darnall BD, Baker LC, et al. Incidence of and risk factors for
chronic opioid use among opioid-naive patients in the postoperative
period. JAMA Intern Med 2016;176:1286–93.
[6] Morita T, Tsunoda J, Inoue S, et al. Contributing factors to physical
symptoms in terminally-Ill cancer patients. J Pain Symptom Manage
1999;18:338–46.
[7] Centers for Disease Control and Prevention. Annual Surveillance Report
of Drug-Related Risks and Outcomes—United States, 2017. Surveillance
Special Report 1. Centers for Disease Control and Prevention, U.S.
Department of Health and Human Services. Published August 31, 2017.
Accessed April 24, 2019 from http://www.cdc.gov/drugoverdose/pdf/
pubs/2017-cdc-drug-surveillance-report.pdf
[8] Hedegaard H, Warner M, Minino AM. Drug overdose deaths in the
United States, 1999-2016. NCHS Data Brief 2017;1–8.
[9] Olfson M, Wall MM, Liu S-M, et al. Cannabis use and risk of
prescription opioid use disorder in the United States. Am J Psychiatry
2018;175:47–53.
[10] Shen JJ, Shan G, Kim PC, et al. Trends and related factors of Cannabis-
Associated Emergency Department visits in the United States: 2006–
2014. J Addict Med 2019;13:193–200.
[11] Fergusson DM, Boden JM, Horwood LJ. Cannabis use and other illicit
drug use: testing the cannabis gateway hypothesis. Addiction 2006;
101:556–69.
[12] Lynch ME, Clark AJ. Cannabis reduces opioid dose in the treatment of
chronic non-cancer pain. J Pain Symptom Manage 2003;25:496–8.
[13] Agency for Healthcare Research and Quality, Quality. Healthcare Cost
and Utilization Project. HCUP Quality Control Procedures. AHRQ.
Available at: http://www.hcup-us.ahrq.gov/db/quality.jsp. Published
August 14, 2018. Accessed August 14, 2018
[14] Agency for Healthcare Research and Quality. Healthcare Cost and
Utilization Project. 2014 Introduction to the NIS. AHRQ. Available at:
http://www.hcup-us.ahrq.gov. Published July 2017. Accessed December
28, 2018
[15] Martin AB, HartmanM, Benson J, et al. Team TNHEA. National Health
Spending In 2014: faster growth driven by coverage expansion and
prescription drug spending. Health Affairs 2017;35:150–60.
[16] Moses H,Matheson DHM, Dorsey ER, et al. The anatomy of health care
in the United States. JAMA 2013;310:1947–63.
[17] Cimasi RJ. Chapter 8. Valuation approaches and methods. In: The four
pillars of healthcare value. John Wiley & Sons, Inc., Hoboken, New
Jersey. 2014.
[18] Agency for Healthcare Research and Quality. Trends in Opioid-Related
Hospitalizations. Content last reviewed July 2018. AHRQ. Available at:
http://www.ahrq.gov/news/opioid-hospitalization-map.html. Published
July 1, 2017. Accessed May 24, 2019
[19] Hasin DS, Sarvet AL, Cerdá M, et al. U. S. adult illicit cannabis use,
cannabis use disorder, and medical marijuana laws. JAMA Psychiatry
2017;74:579–88.
[20] Bachhuber MA, Saloner B, Cunningham CO, et al. Medical cannabis
laws and opioid analgesic overdose mortality in the United States, 1999-
2010. JAMA Intern Med 2014;174:1668–73.
[21] Al-Shammari M, Herrera K, Liu X, et al. Effects of the 2009 medical
cannabinoid legalization policy on hospital use for cannabinoid
dependency and persistent vomiting. Clin Gastroenterol Hepatol
2017;15:1876–81.
[22] Blanco C, Hasin DS, Wall MM, et al. Cannabis use and risk of
psychiatric disorders: prospective evidence From a U.S. National
Longitudinal Study. JAMA Psychiatry 2016;73:388–95.
[23] Dumanovsky T, Augustin R, Rogers M, et al. The growth of
palliative care in U.S. hospitals: a status report. J Palliat Med
2016;19:8–15.
[24] Gani F, Enumah ZO, Conca-Cheng AM, et al. Palliative care utilization
among patients admitted for gastrointestinal and thoracic cancers. J
Palliat Med 2018;21:428–37.
[25] Brumley R, Enguidanos S, Jamison P, et al. Increased satisfaction with
care and lower costs: results of a randomized trial of in-home palliative
care. J Am Geriatr Soc 2007;55:993–1000.
[26] Spetz J, Dudley N, Trupin L, et al. Few hospital palliative care programs
meet national staffing recommendations. Health Aff (Millwood) 2016;
35:1690–7.
[27] Roeland EJ, Triplett DP, Matsuno RK, et al. Patterns of palliative care
consultation among elderly patients with cancer. J Natl Compr Canc
Netw 2016;14:439–45.
[28] Fink RM. Review of a study on late referral to a palliative care
consultation service: length of stay and in-hospital mortality outcomes.
J Adv Pract Oncol 2015;6:597–601.
[29] Temel JS, Greer JA,Muzikansky A, et al. Early palliative care for patients
with metastatic non–small-cell lung cancer. N Engl J Med 2010;
363:733–42.
[30] Temel JS, Greer JA, El-Jawahri A, et al. Effects of early integrated
palliative care in patients with lung and g.i. cancer: a randomized clinical
trial. J Clin Oncol 2017;35:834–41.
[31] Teno JM, Gozalo PL, Bynum JPW, et al. Change in End-of-life
care for medicare beneficiaries: site of death, place of care, and
health care transitions in 2000, 2005, and 2009. JAMA 2013;309:
470–7.
[32] Arnold E, Finucane AM, Oxenham D. Preferred place of death for
patients referred to a specialist palliative care service. BMJ Support
Palliat Care 2015;5:294–6.
[33] Spilsbury K, Rosenwax L, Arendts G, et al. The impact of community-
based palliative care on acute hospital use in the last year of life is
modified by time to death, age and underlying cause of death. A
Population-based Retrospective Cohort Study. PLoS One 2017;12:
e0185275.
[34] Chino FL, Kamal A, Chino JP. Opioid-associated deaths in patients with
cancer: a population study of the opioid epidemic over the past 10 years. J
Clin Oncol 2018;36(30_suppl):230–1230.
[35] Song Z. Mortality quadrupled among opioid-driven hospitalizations,
notably within lower-income and disabled white populations. Health Aff
2017;36:2054–61.
[36] Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and
opioid overdose deaths—United States 2000–2014.MorbidityMortality
Weekly Rep 2016;64:1374–82.
[37] May P, Normand C, Cassel JB, et al. Economics of palliative care for
hospitalized adults with serious illness: a meta-analysis. JAMA Intern
Med 2018;178:820–9.
[38] May P, Garrido MM, Cassel JB, et al. Cost analysis of a prospective
multi-site cohort study of palliative care consultation teams for adults
with advanced cancer: where do cost-savings come from? Palliat Med
2017;31:378–86.
[39] Kim HM, Smith EG, Stano CM, et al. Validation of key behaviourally
based mental health diagnoses in administrative data: suicide attempt,
alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv Res
2012;12:18.
Hwang et al. Medicine (2020) 99:25 www.md-journal.com
9
